Previous Client

Return to Sector or view our Current Clients.

Untitled Document

FluoroPharma Medical, Inc. (FPMI)

FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing two products in clinical trials to fulfill critical unmet medical needs. The agents will provide clinicians important tools for detecting and assessing pathology before critical manifestations of disease.

The company's proprietary molecules labeled with the radioactive isotope of fluorine combined with PET scanning provide non-invasive, highly specific and efficient assessment of heart metabolism and physiology. FluoroPharma's cardiovascular program addresses the largest segment of the nuclear medicine market.

Molecular imaging fulfills numerous unmet needs in diagnosis by enabling visualization, characterization and measurement of biological processes at the molecular and cellular level. Unlike traditional imaging modalities – MRI, CT, and Ultrasound – that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiology and can detect disease before anatomical manifestation is identified. According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future.

FluoroPharma's comprehensive technology platform was developed by scientists at the Massachusetts General Hospital. To date, the company has been issued four US patents and has seven applications pending in addition to strong international protection. With a solid and experienced management team in place and the necessary resources to advance clinical development, FluoroPharma is well positioned to capitalize on its superior imaging technology.

Company Contact
FluoroPharma, Inc.
500 Boylston Street, Suite 1600
Boston, MA 02116

Investor Relations
3370 N. Hayden Rd.
Scottsdale, AZ. 85251

Key Markets
Molecular Imaging

Industry: Healthcare
Sector: Diagnostic Substances
Sub-industry: Molecular Technology

Share Information

CEO & President - Thijs Spoor
Mr. Spoor previously served Sunstone BioSciences as the Chief Financial Officer (CFO). Mr. Spoor holds a Nuclear Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University with concentrations in finance and accounting. Mr. Spoor has been a guest lecturer at Columbia Business School, Kings College in London and the University of Newcastle in Australia and has presented at medical grand rounds and psychiatric grand rounds at various hospitals on the role of brain imaging. Mr. Spoor has also been an equity research analyst at J.P. Morgan and Credit Suisse covering the Biotechnology and Medical Device industries.

Mr. Spoor worked in the pharmaceutical industry spending 10 years with Amersham / GE Healthcare where he worked in 7 countries in a variety of roles including setting up GMP facilities meeting ISO 9001 standards, accountability for the entire nuclear cardiology portfolio and most recently as the Director of New Product Opportunities leading the PET strategic plan.

COO & Vice President Clinical Trials - Boyan Goumnerov, MD
Prior to his appointment with FluoroPharma, Dr. Goumnerov has held executive positions in the healthcare and biomedical research fields; most recent of which are President of VasoStent, Inc. and managing director of CardioVas Inc., start-up medical device companies targeting the field of intravascular cardiac imaging and therapy. His academic background includes research within the departments of Surgery and Molecular Biology at the Massachusetts General Hospital (MGH) and The Shriners Burn Hospital for Children, Boston, where he held academic appointments with Harvard Medical School.

Dr. Goumnerov also did extensive work within the Department of Pathology/Neuropathology at Children's Hospital Boston, in developing image analysis protocols for evaluation of neuromuscular diseases before moving to MGH. He is co-author of numerous scientific publications. Dr. Goumnerov obtained his M.D. from the Medical University of Sofia, Bulgaria, and worked as a clinician prior to relocating to the US.

Chairman and Chief Scientific Advisor - David R. Elmaleh, PhD
Dr. Elmaleh, the scientific founder of FluoroPharma Inc., is an Associate Professor at Harvard Medical School and the Director of Contrast Media Chemistry at the Massachusetts General Hospital. He is an inventor of three drugs that are in use or in late stage clinical trials including: the radiopharmaceutical preparation of (2FDG), which has been used in over a million PET imaging procedures; Beta-methyl modified fatty acid (BMIPP), a commercially successful cardiac SPECT agent; and Altropane, which has completed Phase III clinical trials.


Additional Resources


The QualityStocks

Read the articles covering the biggest movers in the markets today.



Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.


The QualityStocks Daily

Go back to see our previous newsletters and find out what you might have missed.